Combatting the rising costs of cancer drugs; interventions from a university hospital’s perspective

Frontiers in Pharmacology

Pharmacology

Aniek Dane¹  Hugo van der Kuy¹  Roelof van Leeuwen¹  Maaike Hoedemakers²  Stefan Sleijfer³ 

[1] Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands;Department of Market Strategy and Healthcare Financing, Erasmus MC, Rotterdam, Netherlands;Executive Board, Erasmus MC, Rotterdam, Netherlands;

关键词: cancer drugs;    drug life cycle;    university hospital;    precision dosing;    biomarkers;    efficiency;    sustainable healthcare;    self-manufacturing;   

DOI  :  10.3389/fphar.2023.1264951

 received in 2023-07-21, accepted in 2023-08-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

Rapid increase in cost continues to have negative impact on patients’ accessibility to life-changing anticancer medications. Moreover, the rising cost does not equate to similar increase in medication effectiveness. We recognise our responsibility as a university hospital to tackle this imbalance and strive to provide high quality, sustainable, affordable and accessible care. An active approach in cost containment of expensive and innovative cancer drugs was adopted in our organisation to safeguard accessibility and improve quality of life for patients. In this article, we described four inverventions: 1) identify right patient and minimise overtreatment, 2) in-house medicine production for selected indications, 3) minimise medicine spillages and 4) effective procurement strategies. We call on other hospitals to take action and, favourably, to collaborate on a European level. Together, we will safeguard the current and future care of our patients.

【 授权许可】

Unknown   
Copyright © 2023 Dane, van Leeuwen, Hoedemakers, van der Kuy and Sleijfer.